Thursday, October 25, 2012
Publication and contact
BCR-ABL tyrosine kinase
Cell culture studies
suggest Bosulif bosutinib plus danusertib could help treat
CML resistant to Gleevec imatinib. In
primary cancer cells isolated from a patient with Gleevec-resistant CML,
bosutinib and danusertib synergistically decreased cell proliferation
compared with vehicle. The combination did not show a synergistic
antiproliferative effect in cells from a patient with Gleevec-sensitive CML.
Next steps could include testing the combination in a mouse model of
Novartis AG markets the
BCR-ABL inhibitor Gleevec to treat CML and gastrointestinal stromal tumors
Pfizer Inc.'s Bosulif,
a dual inhibitor of BCR-ABL and Src, is approved to treat
Nerviano Medical Sciences s.r.l.'s
kinase inhibitor, danusertib (PHA-739358), is in Phase I
and Phase II testing to treat various cancers.
Published online Oct. 25, 2012
Patent and licensing status
Winter, G.E. et al. Nat.
Chem. Biol.; published online Sept. 30, 2012;
Contact: Giulio Superti-Furga, Research Center for Molecular
Medicine of the Austrian Academy of Sciences, Vienna, Austria
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]